Clinical trials: Obese Adults
Obesity
The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)
The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the…
- Trial name
- AUDACITY (NCT05368259)
- Testing
- AGBS
- Where
- 17 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Allurion Technologies
Obesity
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
- Trial name
- NCT07812597
- Testing
- zovaglutide Arm 1, zovaglutide Arm 2, semaglutide
- Where
- 16 sites in China
- Volunteers
- 210 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Obesity
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate…
- Trial name
- NCT00518466
- Testing
- topiramate, phentermine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Adult Obesity, Weight Management
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction…
- Trial name
- NCT07505303
- Testing
- ECC4703, Semaglutide
- Where
- 15 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Eccogene
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Trial name
- NCT00376285
- Testing
- CP-742,033, Fenofibrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections.
- Trial name
- NCT07605052
- Testing
- Cagrilintide B, Cagrilintide D
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Obesity
Phase 1 Study of NGM313 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
- Trial name
- NCT02708576
- Testing
- NGM313
- Where
- Australia
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Healthy Volunteers, Overweight or Obesity
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered…
- Trial name
- NCT07499050
- Testing
- RO7795081
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult…
- Trial name
- NCT04838405
- Testing
- CT-388
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
NASH, Fatty Liver
Effects of Online App Weight Loss Programs on Liver Health in Obese Adults
The primary objective of this trial is to assess the effects of online app weight loss programs on liver health in obese adults.
- Conditions
- NASH, Fatty Liver, NAFLD, Weight Loss
- Trial name
- NCT05015491
- Testing
- Noom Healthy Weight Program
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Overweight, Obesity
PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals
This is a six month lifestyle management study to compare the effects of iWell; a dynamic online interactive technology to a self-directed program in overweight or obese individuals.
- Trial name
- NCT01325376
- Testing
- Technology assisted health behavior, Self directed
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- SK Telecom Americas, Inc.
Obesity
Safety and Efficacy Study of S-309309 in Obese Adults
The primary objective of this study is to understand the efficacy of S-309309 on the body weight of obese adults.
- Trial name
- NCT05925114
- Testing
- S-309309
- Where
- 49 sites in United States
- Volunteers
- 365 people
- Sponsor
- Shionogi
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- ENLIGHTEN-10 (NCT07900633)
- Testing
- Eloralintide
- Where
- 309 sites in United States, Argentina and 19 more
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are…
- Trial name
- MARITIME-OSA-2 (NCT07226765)
- Testing
- Maridebart cafraglutide
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Insulin Resistance
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet).
- Trial name
- NCT00162799
- Testing
- Triflusal (DCI)
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company